Exponent (NASDAQ: EXPO) grants CFO 10,688 restricted stock units

Rhea-AI Filing Summary

SCHLENKER RICHARD L JR reported acquisition or exercise transactions in this Form 4 filing.

Exponent Inc. reported that EVP & Chief Financial Officer Richard L. Schlenker Jr. received a grant of 10,688 restricted stock units on March 13, 2026. Each unit represents a right to receive one share of common stock on a 1-for-1 basis. Following this compensation-related award, he holds 10,688 restricted stock units directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider SCHLENKER RICHARD L JR

Role EVP & Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	10,688	$0.00	--

Holdings After Transaction: Restricted Stock Units — 10,688 shares (Direct)

Footnotes (1)

1. 1-for-1. Not applicable.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SCHLENKER RICHARD L JR

(Last) (First) (Middle)

149 COMMONWEALTH DRIVE

(Street)

MENLO PARK CA 94025

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
EXPONENT INC [ EXPO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	03/13/2026		A		10,688		03/13/2030	03/13/2030	Common Stock	10,688	(2)	10,688	D

Explanation of Responses:

1. 1-for-1.

2. Not applicable.

	By: Wendy Whitehouse For: Richard L. Schlenker Jr.	03/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Exponent (EXPO) report for its CFO?

Exponent reported that EVP & Chief Financial Officer Richard L. Schlenker Jr. received 10,688 restricted stock units on March 13, 2026. The grant is a stock-based compensation award reported as an acquisition on a Form 4 insider trading report.

How many restricted stock units did Exponent (EXPO) grant to its CFO?

Exponent granted 10,688 restricted stock units to its CFO, Richard L. Schlenker Jr. These units were awarded on March 13, 2026 and are reported as a derivative security linked to the company’s common stock on a one-for-one conversion basis.

What does the 1-for-1 footnote mean in the Exponent (EXPO) Form 4?

The 1-for-1 footnote means each restricted stock unit is convertible into one share of Exponent common stock. This links the value of the award directly to the company’s share price, aligning the executive’s compensation with shareholder outcomes over time.

What is the total position reported after the Exponent (EXPO) RSU grant?

After the transaction, the Form 4 shows Richard L. Schlenker Jr. holding 10,688 restricted stock units directly. This figure reflects the reported derivative holdings following the March 13, 2026 grant of restricted stock units tied to Exponent’s common stock.

Was the Exponent (EXPO) CFO’s RSU grant a market purchase or sale?

The transaction was a grant of restricted stock units, not a market purchase or sale. It is categorized as a derivative award with zero purchase price, representing stock-based compensation rather than an open-market trade in Exponent shares.